Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Exploiting poly(I:C) to induce cancer cell apoptosis.

Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L.

Cancer Biol Ther. 2017 Oct 3;18(10):747-756. doi: 10.1080/15384047.2017.1373220. Epub 2017 Sep 7.

2.

Toll-Like Receptor 9 Agonists for Cancer Therapy.

Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, Tortora G.

Biomedicines. 2014 Aug 4;2(3):211-228. doi: 10.3390/biomedicines2030211. Review.

3.

Chemically Programmed Bispecific Antibodies in Diabody Format.

Walseng E, Nelson CG, Qi J, Nanna AR, Roush WR, Goswami RK, Sinha SC, Burke TR Jr, Rader C.

J Biol Chem. 2016 Sep 9;291(37):19661-73. doi: 10.1074/jbc.M116.745588. Epub 2016 Jul 21.

4.

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.

De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Deraco M, Balsari A, Zaffaroni N.

J Transl Med. 2016 Jan 25;14:25. doi: 10.1186/s12967-016-0781-4.

5.

CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Jordan M, Waxman DJ.

Cancer Lett. 2016 Apr 1;373(1):88-96. doi: 10.1016/j.canlet.2015.11.029. Epub 2015 Dec 3.

6.

Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Santhanam S, Alvarado DM, Ciorba MA.

Transl Res. 2016 Jan;167(1):67-79. doi: 10.1016/j.trsl.2015.07.003. Epub 2015 Aug 3. Review.

8.

Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.

Li TT, Ogino S, Qian ZR.

World J Gastroenterol. 2014 Dec 21;20(47):17699-708. doi: 10.3748/wjg.v20.i47.17699. Review.

9.

Pattern recognition receptors and DNA repair: starting to put a jigsaw puzzle together.

Kutikhin AG, Yuzhalin AE, Tsitko EA, Brusina EB.

Front Immunol. 2014 Jul 23;5:343. doi: 10.3389/fimmu.2014.00343. eCollection 2014. Review. No abstract available.

10.

Toll-like receptor-4 deficiency enhances repair of UVR-induced cutaneous DNA damage by nucleotide excision repair mechanism.

Ahmad I, Simanyi E, Guroji P, Tamimi IA, delaRosa HJ, Nagar A, Nagar P, Katiyar SK, Elmets CA, Yusuf N.

J Invest Dermatol. 2014 Jun;134(6):1710-1717. doi: 10.1038/jid.2013.530. Epub 2013 Dec 10.

11.

CpG oligodeoxynucleotides enhance chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells via downregulation of the antiapoptotic factors survivin and livin.

Liang SR, Hu GR, Fang LJ, Huang SJ, Li JS, Zhao MY, Meng MJ.

Cancer Cell Int. 2013 Oct 26;13(1):106. doi: 10.1186/1475-2867-13-106.

12.

Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects.

Fűri I, Sipos F, Germann TM, Kalmár A, Tulassay Z, Molnár B, Műzes G.

World J Gastroenterol. 2013 Jul 14;19(26):4119-26. doi: 10.3748/wjg.v19.i26.4119. Review.

13.

Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo.

Wang X, Wang L, Wan M, Wu X, Yu Y, Wang L.

Nucleic Acid Ther. 2013 Aug;23(4):253-63. doi: 10.1089/nat.2013.0419. Epub 2013 Jul 13.

14.

Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells.

Yang KL, Wang YS, Chang CC, Huang SC, Huang YC, Chi MS, Chi KH.

PLoS One. 2013 Apr 25;8(4):e61797. doi: 10.1371/journal.pone.0061797. Print 2013.

15.

Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.

De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari S, Mezzanzanica D, Iorio MV, Tagliabue E, Balsari A.

PLoS One. 2013;8(3):e58849. doi: 10.1371/journal.pone.0058849. Epub 2013 Mar 6.

16.

High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.

Sommariva M, de Cesare M, Meini A, Cataldo A, Zaffaroni N, Tagliabue E, Balsari A.

J Transl Med. 2013 Jan 29;11:25. doi: 10.1186/1479-5876-11-25.

17.

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells?

Sommariva M, De Cecco L, Tagliabue E, Balsari A.

Oncoimmunology. 2012 Mar 1;1(2):258-259.

Supplemental Content

Support Center